Protara Therapeutics Inc (TARA) Return on Equity ROE from the second quarter 2026 to second quarter 2024 and annually, average high and low, overall ranking from Jun 30 2026 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Protara Therapeutics Inc  (NASDAQ: TARA)

Protara Therapeutics Inc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Protara Therapeutics Inc in the second quarter 2026?
Protara Therapeutics Inc recorded a cumulative net loss of $-67 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -42.36%.

Within the Biotechnology & Pharmaceuticals industry 42 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2025 from 2871 to 3094.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Equity Change -3.48 % 140.14 % 43.72 % 147.27 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -67 -58 -52 -48 -45
Return On Equity (TTM) -42.36 % -36.42 % -39.73 % -39.94 % -44.67 %
TARA's Total Ranking # 3094 # 2871 # 2847 # 2682 # 2436
Equity (TTM) in Millions 161 196 132 144 167
Seq. Equity Change -17.87 % 48.47 % -8.4 % -13.59 % 104.34 %
Seq. Net Income Change - - - - -

Back to TARA Management Effectiveness >> TARA's 5 Years Annual ROE >> Compare TARA ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 43
Sector # 371
Overall # 3094

Return On Equity Statistics
High Average Low
-10.27 %
-78.23 %
-794.84 %
(Sep 30 2015)   (Dec 31 2019)



  News about Protara Therapeutics Inc Return on Equity ROE

Protara Therapeutics Secures $45 Million in Private Placement Funding, Securing Cash Runway Extension up to 2026



Protara Therapeutics, a renowned innovative biopharmaceutical company, has recently announced the successful completion of an oversubscribed $45 million private placement financing round. The funding is expected to be instrumental in advancing the company s revolutionary drug development programs and extending its cash runway well into 2026. This significant achievement showcases the strong investor confidence in Protara s groundbreaking therapies and highlights the potential for robust growth and success in the coming years.
Recognizing the company s accomplishments and its unique position within the healthcare industry, Protara Therapeutics latest financing milestone exemplifies the resolve and strategic brilliance driving the organization forward.



TARA Annual Return On Equity (Mar 31 2026)
2026		 (Mar 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022
Total Equity in Millions 181 158 167 68 102
Y / Y Equity Change 14.34 % -5.18 % 144.63 % -33.07 % -36.95 %
Net Income in Millions -18 -12 -45 -40 -66
Y / Y Net Income Change - - - - -
Return On Equity -9.81 % -7.52 % -26.68 % -59.16 % -64.61 %

Back to TARA Management Effectiveness >> TARA's 5 Years Annual ROE >> Compare TARA ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
TARA's' Return on Equity at Yahoo Finance
TARA's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for TARA's Competitors
Subscribers only: Roe for Protara Therapeutics Inc's Suppliers
Subscribers only: Return On Equity for TARA's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE

Date modified: 2026-09-26T07:10:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.